Bruker Corporation (NASDAQ:BRKR) Given Average Recommendation of “Hold” by Analysts

Bruker Corporation (NASDAQ:BRKR) has been assigned a consensus recommendation of “Hold” from the sixteen brokerages that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $50.6154.

A number of research analysts have recently issued reports on BRKR shares. Zacks Research upgraded shares of Bruker from a “strong sell” rating to a “hold” rating in a report on Monday, December 8th. The Goldman Sachs Group started coverage on shares of Bruker in a research report on Tuesday. They issued a “sell” rating and a $40.00 price target on the stock. TD Cowen boosted their price objective on Bruker from $40.00 to $42.00 and gave the stock a “hold” rating in a report on Tuesday, November 4th. Cowen reissued a “hold” rating on shares of Bruker in a research note on Tuesday, November 4th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Bruker in a research report on Monday, December 1st.

Insider Activity

In other news, Director John A. Ornell sold 6,233 shares of the stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $39.00, for a total value of $243,087.00. Following the completion of the sale, the director owned 35,212 shares in the company, valued at $1,373,268. This represents a 15.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 27.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Bruker

A number of institutional investors have recently added to or reduced their stakes in the company. Orbis Allan Gray Ltd purchased a new stake in Bruker in the 2nd quarter valued at about $192,735,000. AQR Capital Management LLC grew its holdings in shares of Bruker by 125.3% in the second quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock valued at $137,065,000 after acquiring an additional 1,850,215 shares in the last quarter. Sculptor Capital LP increased its position in shares of Bruker by 18.3% during the second quarter. Sculptor Capital LP now owns 3,074,801 shares of the medical research company’s stock valued at $126,682,000 after acquiring an additional 476,363 shares during the last quarter. Brown Advisory Inc. lifted its holdings in Bruker by 13.9% during the second quarter. Brown Advisory Inc. now owns 2,746,163 shares of the medical research company’s stock worth $113,142,000 after acquiring an additional 336,026 shares during the period. Finally, Vaughan Nelson Investment Management L.P. boosted its position in Bruker by 61.6% in the third quarter. Vaughan Nelson Investment Management L.P. now owns 2,090,155 shares of the medical research company’s stock worth $67,909,000 after purchasing an additional 796,510 shares during the last quarter. 79.52% of the stock is owned by institutional investors.

Bruker Trading Down 2.7%

NASDAQ BRKR opened at $45.13 on Friday. The company has a quick ratio of 0.91, a current ratio of 1.85 and a debt-to-equity ratio of 0.81. Bruker has a 52 week low of $28.53 and a 52 week high of $64.64. The business has a 50 day moving average price of $41.68 and a 200-day moving average price of $38.32. The company has a market cap of $6.86 billion, a price-to-earnings ratio of -282.06, a P/E/G ratio of 6.82 and a beta of 1.17.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings results on Monday, November 3rd. The medical research company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.33 by $0.12. The business had revenue of $860.50 million during the quarter, compared to the consensus estimate of $847.40 million. Bruker had a negative net margin of 0.61% and a positive return on equity of 15.45%. Bruker’s revenue was down .5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.60 EPS. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. As a group, equities analysts expect that Bruker will post 2.69 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 2nd. Shareholders of record on Monday, December 8th will be issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Monday, December 8th. Bruker’s payout ratio is currently -125.00%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.